Jazz Pharmaceuticals (JAZZ) Stock Overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
JAZZ Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Jazz Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$137.64 |
| 52 Week High | US$148.06 |
| 52 Week Low | US$95.49 |
| Beta | 0.28 |
| 1 Month Change | -1.32% |
| 3 Month Change | 18.55% |
| 1 Year Change | 24.62% |
| 3 Year Change | -6.00% |
| 5 Year Change | -7.44% |
| Change since IPO | 676.31% |
Recent News & Updates
Recent updates
Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating
Sep 24Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
Jul 21Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
Jul 03Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts
May 09Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist?
Apr 27Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apr 09Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
Feb 22With EPS Growth And More, Jazz Pharmaceuticals (NASDAQ:JAZZ) Makes An Interesting Case
Jan 12Sentiment Still Eluding Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Dec 25Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Dec 23Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve
Nov 14Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19
Xywav And Epidiolex Drive Market Penetration And Promise Robust Revenue Growth Amid Strategic Shifts And Innovation Focus
Strategic diversification and investments in R&D aim to reduce reliance on the oxybate franchise, focusing on oncology and Epidiolex for future growth.Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Shareholder Returns
| JAZZ | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.6% | 1.8% | 0.5% |
| 1Y | 24.6% | 2.1% | 20.1% |
Return vs Industry: JAZZ exceeded the US Pharmaceuticals industry which returned 2.1% over the past year.
Return vs Market: JAZZ exceeded the US Market which returned 20.1% over the past year.
Price Volatility
| JAZZ volatility | |
|---|---|
| JAZZ Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JAZZ has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: JAZZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,800 | Renee Gala | www.jazzpharma.com |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder.
Jazz Pharmaceuticals plc Fundamentals Summary
| JAZZ fundamental statistics | |
|---|---|
| Market cap | US$8.35b |
| Earnings (TTM) | -US$404.84m |
| Revenue (TTM) | US$4.09b |
Is JAZZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAZZ income statement (TTM) | |
|---|---|
| Revenue | US$4.09b |
| Cost of Revenue | US$321.40m |
| Gross Profit | US$3.77b |
| Other Expenses | US$4.17b |
| Earnings | -US$404.84m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | -6.67 |
| Gross Margin | 92.14% |
| Net Profit Margin | -9.91% |
| Debt/Equity Ratio | 144.7% |
How did JAZZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 16:55 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jazz Pharmaceuticals plc is covered by 48 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Brian Skorney | Baird |
| null null | Baird |